An individualized neoantigen mRNA vaccine was tested in patients with early-stage triple-negative breast cancer and showed feasibility, safety, and strong T cell immune responses. Long-term follow-up ...

A new addition to the mRNA analytics toolbox enables fast, accurate, and easy-to-use sample analysis while keeping RNA molecules in their native state.

Moderna says its experimental mRNA influenza vaccine, mRNA-1010, showed more than 30% greater relative vaccine efficacy against influenza A than a licensed egg-based flu shot in a large Phase 3 trial ...

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

One week after saying it was refusing to review Moderna’s application for approval of a new flu vaccine, the US Food and Drug Administration's (FDA’s) Center for Biologics Evaluation and Research ...

The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is “part of a disturbing pattern” of moving regulatory goalposts, according to Clay Alspach, executive director of the Alliance for mRNA ...

As the U.S. backpedals on its mRNA investment, Mexico is embracing the technology through a new manufacturing pact with ...

Australia has begun a pioneering clinical trial using personalized mRNA vaccines to treat children and adolescents with ...

Sanofi has discontinued development of its next-generation mRNA-based seasonal flu vaccine. According to its 2025 earnings documents, the drugmaker said it halted its phase 1 trial for an mRNA ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice. The ...